Jazz Pharmaceuticals says a second interim analysis of HERIZON-GEA-01 found statistically significant and clinically meaningful overall survival improvement with Ziihera plus chemotherapy versus trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma.
Roche has secured expanded FDA approval for two HER2 companion diagnostics used to identify gastroesophageal adenocarcinoma patients who may be eligible for Jazz Pharmaceuticals’ ZIIHERA.
FDA has approved two Ziihera-based first-line regimens in HER2-positive advanced gastroesophageal adenocarcinoma after the Tevimbra combination improved median overall survival from 19.2 to 26.4 months.
Find out how BeOne’s HERIZON-GEA data could reshape HER2-positive gastroesophageal cancer treatment after ASCO 2026.